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Background: Accurate cause of death assignment is crucial for prostate cancer epidemiology and trials reporting prostate cancer-
specific mortality outcomes.
Methods:We compared death certificate information with independent cause of death evaluation by an expert committee within
a prostate cancer trial (2002–2015).
Results: Of 1236 deaths assessed, expert committee evaluation attributed 523 (42%) to prostate cancer, agreeing with death
certificate cause of death in 1134 cases (92%, 95% CI: 90%, 93%). The sensitivity of death certificates in identifying prostate cancer
deaths as classified by the committee was 91% (95% CI: 89%, 94%); specificity was 92% (95% CI: 90%, 94%). Sensitivity and
specificity were lower where death occurred within 1 year of diagnosis, and where there was another primary cancer diagnosis.
Conclusions: UK death certificates accurately identify cause of death in men with prostate cancer, supporting their use in routine
statistics. Possible differential misattribution by trial arm supports independent evaluation in randomised trials.
Prostate cancer is the second commonest cause of cancer death in
UK men (UK National Screening Committee, 2015). Death
certificates are used in routine mortality statistics, large-scale
epidemiological studies and randomised controlled trials. However,
prostate cancer can be misattributed as the underlying cause of
death on death certificates in men diagnosed with prostate cancer
(Feuer et al, 1999). A review of US medical records (Albertsen et al,
2000) suggested that 29% of men with prostate cancer as the
underlying cause of death on death certificates had died of some
other condition (Albertsen et al, 2000).
The possibility of differential attribution bias in trials, where the
primary end point is prostate cancer-specific mortality, is also a
concern (Black et al, 2002). All-cause mortality is least open to bias
(Black et al, 2002), but because prostate cancer death is relatively
uncommon (UK National Screening Committee, 2015), all-cause
mortality is less sensitive to the effects of screening.
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The possibility of attribution bias has led us and others (Miller
et al, 2000; de Koning et al, 2003; Miller et al, 2015) to conclude
that assignment of the underlying cause of death in prostate cancer
trials must be confirmed by an independent expert (CoDE)
committee. We have compared the underlying cause of death
determined by an independent CoDE committee, with the
underlying cause of death listed on official death certificates in
UK men with prostate cancer participating in a UK-wide trial
(Lane et al, 2014; Turner et al, 2014).
METHODS
Follow-up and identification of a prostate cancer-related event.
All 413 000 men enrolled in the Cluster randomised trial of PSA
testing for prostate cancer (CAP) trial have been traced and flagged
for vital status follow-up at the Health and Social Care Information
Centre (Turner et al, 2014). Blinded to death certificate and
underlying cause of death, detailed information was obtained
from the medical records of all men with a potential prostate
cancer death (see Supplementary Table 1 for the triggers used to
review a potential prostate cancer death), and used to generate a
short structured clinical vignette (Williams et al, 2015); (see
Supplementary Material 1).
Determination of cause of death. Members of an international
CoDE committee reviewed the vignettes. They completed a
questionnaire that when followed in sequence, and using detailed
definitions adapted from the European Randomised Study of
Screening for Prostate Cancer trial (de Koning et al, 2003) acted as
an algorithm for assigning cause of death into the following
categories: definite, probable, possible, unlikely or definitely not
prostate cancer, and definite or probable intervention-related
mortality (Supplementary Material 2). The committee was divided
into three teams, each comprising four consultants from the
following specialties: pathology, palliative care, urology and cancer
surgery (see Figure 1 and Supplementary Material 1). The death
certificate underlying cause of death was accepted where a review
was not triggered (i.e., in the absence of a potential prostate cancer
death, these were recorded as due to other causes).
Analysis. We examined the agreement between prostate cancer
assigned as the underlying cause of death on the death certificate
with prostate cancer (definite, probable or intervention-related)
assigned as the cause of death after expert review. We calculated
‘sensitivity’ as the proportion of confirmed prostate cancer deaths
as assigned by the expert review process (denominator), which
were listed as an underlying cause of death of prostate cancer on
the death certificate (numerator) (Box 1). We calculated ‘specificity’ as
proportion of confirmed non-prostate cancer deaths as above. Each
of sensitivity and specificity are accompanied by exact binomial
(Clopper–Pearson) confidence intervals (Clopper and Pearson,
1934). We investigated whether sensitivity and specificity varied by
age-group (splitting age at death into three groups of approximately
equal size), the interval between date of diagnosis and date of death,
and the presence of another cancer diagnosis. All parameters were
calculated with their respective 95% confidence intervals.
Ethics. Ethical approval was provided by Trent Research Ethics
Committee (MREC/01/4/025; MREC/03/4/093; 05/MRE04/78) and
the Confidentiality Advisory Group (PIAG 4–09 (k)/2003; PIAG 1-
05(f)/2006).
RESULTS
Over 50 000 deaths were notified to the CAP investigators by the
Health and Social Care Information Centre between 2002 and
2015. Of these, 2069 men had died of a potential prostate cancer-
related death, and the underlying cause of death has been
established for 1236 (60%) of these men to date.
Table 1 shows the number of deaths assigned as prostate
cancer or other cause on the death certificates compared with the
expert review process. Of a total of 1236 potential prostate
cancer-related deaths, the independent CoDE committee attrib-
uted 523 (42%) to prostate cancer and 713 (58%) to other causes.
The corresponding cause of death categories based on death
certificates were 535 (43%) and 701 (57%), respectively. The
expert committee agreed with death certificate derived under-
lying cause of death (prostate cancer or other) in 1134 cases (92%
agreement, 95% CI: 90, 93%).
Eight per cent of deaths categorised as due to other causes
after review of the case vignettes had been assigned as prostate
cancer on death certificates (death certificate specificity: 92%;
95% CI: 90%, 94%). On the other hand, 9% of deaths classified as
due to prostate cancer by the reviewers were assigned to other
causes on the death certificates (death certificate sensitivity: 91%;
95% CI: 89%, 94%).
For men who died within 1 year of their diagnosis of prostate
cancer, the death certificates had a sensitivity of 78% (95% CI:
69%, 85%) and specificity of 87% (95% CI: 80%, 93%); for men
who died between 1 and 3 years of diagnosis, specificity was 87%
(95% CI: 80%, 92%) and sensitivity was 93% (95% CI: 89%, 96%).
The presence of another cancer diagnosis, either notified by
Health and Social Care Information Centre or present on the
death certificate, was also associated with a lower sensitivity
(77%; 95% CI: 65%, 86%) and specificity (89%; 95% CI: 85%,
91%). The age at death had little impact on sensitivity or
specificity. Three of the 1236 deaths were categorised as
intervention-related deaths by the committee.
DISCUSSION
These data suggest that relying on underlying cause of death
abstracted from official UK death certificates rather than an
independent expert committee would result in some misattribu-
tion. Specifically, 9% of deaths assigned as being due to prostate
cancer by the CoDE committee were recorded on death
certificates as deaths from other causes (false negatives), and
8% of deaths considered on the death certificate to be due to
prostate cancer were assigned to other causes (false positives) by
the expert review. The impact of age was minimal, suggesting the
use of UK death certificates could provide a relatively accurate
means of evaluating population trends in prostate cancer
mortality. However, where there was a death within 1 year of
diagnosis of prostate cancer, both false positives (22%) and false
negatives (13%) increased. This could reflect a tendency for
competing causes of death to be less frequently considered by
doctors completing death certificates when a prostate cancer
diagnosis has only recently been made. The presence of another
primary cancer, either on the death certificate or diagnosed as
alive, also resulted in increased false positives (23%) and false
negatives (11%). This could be because the clinical picture is
unclear in these cases.
These results are based only on those deaths that were triggered
for in-depth review by the expert committee because they were
potential prostate cancer deaths. We did not review the other
49 000 deaths where there was no evidence of prostate cancer ever
being diagnosed or where there was no evidence of other
conditions that could have indicated a potential prostate cancer
death, such as bone cancer (conceptualised as a potential
misclassified bony metastasis). If all these other 49 000 deaths are
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correctly assumed not to be due to prostate cancer, this will have
resulted in near perfect specificity for all deaths.
Similar level of agreement between death certification and expert
review were observed in the USA (Albertsen et al, 2000), Sweden
(Godtman et al, 2011) and Finland (Makinen et al, 2008). Common
reasons for misclassification were cardiovascular or cancer co-
morbidities (Albertsen et al, 2000). In a recent study (Miller et al,
2015), agreement between death certificate and death review committee
was 490%, but death certificated causes of death missed treatment-
related deaths and the misattribution was differential by trial arm.
The study’s strength was that it was based on large trials, we
identified intervention-related deaths, and we successfully masked
the trial arm from the expert committee (Williams et al, 2015),
even though this was reported to be difficult in another trial (Barry
et al, 2013). Limitations are that the results may not be
generalisable beyond the cohorts included in the trials, and the
assumption that CoDE results were near perfect in accuracy.
UK death certificates provide a relatively accurate means for
evaluating cause of death that would be acceptable for routine
public health monitoring and large-scale epidemiological studies.
Study vignette completed
Phase one review: 2 reviewers each independently assign UCD
Phase two review: 2 more reviewers*: each independently
assign UCD
Reviewers disagree
3 out of 4
reviewers
agree
‘Odd-one-out’
reconsiders
‘Odd-one-out’
disagrees with
majority
‘Odd-one-
out’ agrees
with majority
Both
reviewers
agree
Assign final UCD
Disagree
Annual review by
whole committee – 1
form completed
Triage phase by independent
reviewer. No evidence at all of local
or distal prostate cancer progression
or intervention related deaths –
Accept death certificate UCD.
Evidence found on review - enter
phase one
Further
information may
be requested if
vignette deemed
incomplete
*Reviewers rotated from amongst the three review teams.
UCD = Underlying cause of death
Figure 1. Process for evaluating cause of death.
Box 1. Calculation of sensitivity and specificity
Sensitivity ¼ N of PCa deaths ðagreement between CoDE and death certificationÞ
Total N of PCa deaths reviewed
100
Specificity ¼N of deaths other causes ðagreement between CoDE and death certificationÞ
Total N of deaths other causes reviewed
100
PCa¼ prostate cancer
CoDE¼ cause of death evaluation
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In the context of randomised controlled trials, the potential for
even a small amount of misattribution bias that is differential by
trial arm means that an independent cause of death evaluation is
likely to be necessary to provide unbiased outcome data.
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